How long is long enough for pharmacological thromboprophylaxis in urology?
Why the study?
Does extended pharmacological thromboprophylaxis reduce venous thromboembolism in patients undergoing urological surgery?
Population
Patients undergoing urological surgery (e.g., radical prostatectomy, radical cystectomy, nephrectomy)
Comparison
Extended pharmacological thromboprophylaxis vs In-hospital-only or standard duration prophylaxis
Design
Editorial
Authors
Discussion
Loading...
Member takes
Implication
Extended pharmacological thromboprophylaxis is a reasonable evidence-based approach for urological surgery patients at high risk of VTE, though definitive optimal duration requires large-scale RCTs.
Structured PICO
Does extended pharmacological thromboprophylaxis reduce venous thromboembolism in patients undergoing urological surgery?
P
Population
Patients undergoing urological surgery (e.g., radical prostatectomy, radical cystectomy, nephrectomy)
I
Intervention
Extended pharmacological thromboprophylaxis (e.g., low-molecular-weight heparin for at least 14 days or up to 4 weeks)
C
Comparator
In-hospital-only or standard duration prophylaxis
O
Outcome
Venous thromboembolism (VTE)hard clinical
Extended pharmacological thromboprophylaxis is a reasonable evidence-based approach for urological surgery patients at high risk of VTE, though definitive optimal duration requires large-scale RCTs.
Limitations
- Lack of urology-specific studies comparing in-hospital-only to extended prophylaxis
- Included studies were observational with limited adjustment for confounders
Cite This Study
Tikkinen et al. (2019) studied this question.